ADMA Biologics, Inc. (Nasdaq:ADMA) today announced its lead product candidate RI-002 has demonstrated positive Phase III results and successfully achieved its primary endpoint.
ADMA Biologics, Inc. (OTCQB:ADMA) today announced that the NASDAQ stock market has approved ADMA's common stock for listing on the NASDAQ Capital Market and is expected to begin trading on November 10, 2014 under the symbol "ADMA."
Alcon, the global leader in eye care and the second largest division of Novartis Group, announced today that the company has entered into an agreement to acquire WaveTec Vision.
Lentigen Corporation, a global leader in lentiviral technology for cell and gene therapy applications, today announced the sale of its lentiviral vector manufacturing business and related assets to Miltenyi Biotec, who will operate through its newly formed, wholly-owned US subsidiary Lentigen Technology, Inc.
Strand Life Sciences Pvt. Ltd. and Health Care Global Enterprises Ltd. are proud to announce the launch of The Strand Triesta Center For Cancer Genomics at a symposium on Clinical Genomics: New Generation Cancer Care.
HealthCare Global (HCG) Enterprises Ltd, The Specialists in Cancer Care, creates a new benchmark in cancer care by making genomics-based diagnostics, a ‘standard-of-care’ for cancer treatment in India. These diagnostic tests will support physicians, and their patients with the most accurate and advanced tumor profiling of large number genes for “actionable” mutations. The information about these mutations helps to identify targeted therapies and treatment choices early in the course of cancer care.
Curie-Cancer, the body responsible for developing Institut Curie's industry partnership activity, and Strand Scientific Intelligence, Inc. (Strand) announce the launch of the Curie Image Database (CID), a breakthrough image analysis and management platform that they developed jointly over the last two years at the Cell and Tissue Imaging Core Facility of the Institut Curie (PICT-IBiSA).
Strand Life Sciences Private Limited, a global life sciences company headquartered in Bangalore, is collaborating with the San Francisco Bay Area based El Camino Hospital to locate a Strand Center for Genomics and Personalized Medicine at the Genomic Medicine Institute of the El Camino Hospital to accelerate the adoption of next generation sequencing based research panels and counseling services by the physicians at the Hospital and its partner clinics.
Strand Life Sciences, a bioinformatics company whose products for Array, Mass Spec and NGS analysis are used by over 2000 laboratories worldwide and has recently developed solutions in the field of clinical diagnostics, is launching its Early Access Program for its clinical genomics interpretation and reporting platform. Strand’s clinical application is a deep interpretation and reporting system for clinical genomics. It was designed in collaboration with clinicians while working on real patient cases in Strand’s clinical laboratory, and therefore provides the necessary information to help medical practitioners confidently deliver clinical reports with ease.
Strand Life Sciences, a bioinformatics company whose products for Array, Mass Spec and NGS analysis are used by over 2000 laboratories worldwide and has recently developed solutions in the field of clinical diagnostics, is launching its Early Access Program for its clinical genomics interpretation and reporting platform. Strand’s clinical application is a deep interpretation and reporting system for clinical genomics. It was designed in collaboration with clinicians while working on real patient cases in Strand’s clinical laboratory, and therefore provides the necessary information to help medical practitioners confidently deliver clinical reports with ease. “Strand is combining its clinical laboratory experience with its formidable computational expertise to build an application that accelerates clinical genomics interpretation and reporting,” said Dr. Vijay Chandru, CEO of Strand, “and we are excited to launch our Early Access Program to make this platform accessible to other labs who could benefit from its use.”
On BetterDoctor, which functions like an “Opentable for doctors,” you can search for a health care expert in a range of specialties. Its database features one million doctors and other care providers, located in various cities around the country. Most of these doctors have never heard of BetterDoctor. The startup’s team of programmers have scraped Yelp, hospital listings, private practice sites, and the like to create custom profiles for doctors with reviews and location information. Many of these doctors will only hear about BetterDoctor, after they experience a spike in patient requests and foot traffic.
ADMA Biologics, Inc. (OTCQB: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced the pricing of its initial public offering of 3,352,941 shares of its common stock at a public offering price of $8.50 per share. All of the shares of common stock are being offered by ADMA Biologics. In addition, ADMA Biologics has granted the underwriters a 30-day option to purchase up to an additional 502,941 shares of common stock at the same price to cover over-allotments, if any. The company's shares are expected to begin trading on The OTCQB Marketplace on October 17, 2013 under the ticker symbol “ADMA.”
On March 13, 2013, leaders from JHL Biotech and GE Healthcare Life Sciences signed a strategic cooperation agreement. The two companies will build a monoclonal antibody manufacturing plant in Wuhan’s Biolake Science Park. Many executives from Biolake participated, including Deputy Director of East Lake High-Tech Zone, Director of Biological Department, Changchun Dan and Biological department leaders Zhongyu Yan and Yunhua Yuan.
MabVax Therapeutics has received a contract from the National Cancer Institute under the Small Business Innovation Research Technology Program (SBIR). The award is in the amount of $1,750,000 over the next three years and will support development of a novel positron emission tomography (PET)imaging product for the diagnosis, staging, and treatment assessment of pancreatic cancer.
WhiteGlove Health, (WGH) a leading service driven and outcomes-oriented healthcare provider, focusing on enhancing quality and improving the consumers’ healthcare experience while lowering the cost, today announced the appointment of Nicholas A. Balog, MPH as Chief Executive Officer. He will be responsible for leading the organization and advancing the company’s strategic vision while ensuring excellence in its service delivery.
On March 13, 2013, leaders from JHL Biotech and GE Healthcare Life Sciences signed a strategic cooperation agreement. The two companies will build a monoclonal antibody manufacturing plant in Wuhan’s Biolake Science Park. Many executives from Biolake participated, including Deputy Director of East Lake High-Tech Zone, Director of Biological Department, Changchun Dan and Biological department leaders Zhongyu Yan and Yunhua Yuan.
Cordis Corporation, a worldwide leader in the development of interventional vascular technology, today announced it has completed the acquisition of Flexible Stenting Solutions, Inc., a leading developer of innovative flexible peripheral arterial, venous and biliary stents.
Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced today that that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to P140K methylguanine methyltransferase (MGMT) transduced human CD34 cells (product name: LG631-CD34) for bone marrow protection in the treatment of glioblastoma multiforme. Orphan drug designation qualifies Lentigen for seven years of market exclusivity following marketing approval by the FDA and provides other development-related incentives.
The proceeds of the financing of the Series B is to accelerate the growth of the company's evolution into precision diagnostics in healthcare and expand Strand's reach into global markets. Strand will leverage its expertise in genomics and analytics that it has developed over a decade. In taking its technology platforms from bench to bedside, Strand is uniquely positioned to bring the power of high precision genomic measurement methods such a Next Generation Sequencing (NGS) to applications in screening and identification of diseases with genetic-basis and in precisely classifying cancer types to personalize therapy and care.
MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of proprietary immunotherapies to address the unmet medical need of preventing recurrent cancer, today announced the closing of the first tranche in their Series B financing. Numoda Capital Innovations led the round and was joined by existing investors Burrill Capital Fund IV and RTP Venture Fund for an aggregate investment of $5.25 million. The additional capital will allow MabVax to continue the development of its phase 2 vaccine aimed at preventing recurrent sarcoma and its 5B1 antibody program targeting metastatic pancreatic cancer.